IJTLD Open (ISSN: 3005-7590) is open access and fully compliant with Plan S.
IJTLD Open includes a broader range of article types than the traditional IJTLD, including: Editorials, Meeting reports, Original Articles (including methodology papers, qualitative research and operational research), State of the Art Reviews, Guidelines/Consensus documents, Systematic Reviews and Meta-Analysis, Perspectives, Minireviews, Letters, Case reports, Case series and Correspondence.
We publish high impact research for the continuing education of academics, clinicians and all other health personnel working on respiratory diseases and lung health, with the aim of improving policy and practise.
IJTLD OPEN is open access and free to read. Also, authors retain copyright and can freely distribute the PDF or upload it to any website. As a consequence, open access articles are highly downloaded and more highly cited.
Click the links below to read our content on PubMed Central, Ingenta.com or via links from the Directory of Open Access Journals (DOAJ), or PubMed. .
While preparing their article, authors should refer to the Instructions for Authors to check that they have complied with our requirements – see links below.
Once complete, authors should submit their manuscripts at http://mc.manuscriptcentral.com/ijtld
We invite authors with OA funding to submit their papers (including Editorials, Original Articles, Letters and Case Series) to IJTLD OPEN.
We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.
This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
For all queries please e-mail the Editorial Office
Sponsorship
Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.
Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.
All content will be freely available on Ingenta.com and we will have regular mailings to highlight the latest sponsored content.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
Adapting TB services during the COVID-19 pandemic in Mumbai, India
A letter to the Editors of the IJTLD on adaptations to TB services that could help ensure continuity of services for RR/MDR-TB during COVID-19.
Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria
Letter to the editors giving an early view into the impact of COVID-19 on TB diagnosis in Nigeria, a high burden setting for TB.
How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease
A letter to the editors of the IJTLD which highlights the need to mitigate the risk of researchers being exposed to TB and other airborne pathogens.
COVID-19 and TB control in immigrant communities
Letter to the editors highlighting the disparity of impact of COVID-19 and TB on immigrant communities and the need to have affordable healthcare.
How TB and COVID-19 compare: an opportunity to integrate both control programmes
Letter to the editors which highlights similarities and differences between TB and COVID-19 – and proposes that control programmes unite to address both conditions.
COVID-19: ensuring continuity of TB services in the private sector
Pakistan has the fifth largest global burden of TB, and in response to COVID-19 a lockdown was imposed on 26 February. TB services were severely disrupted. This threatened to undermine recent gains in private-sector engagement and TB elimination efforts.